Organon & Co. (OGN)

Women's health and biosimilars drug maker, 15% U.S. Read October 19, 2026 from the annual report for the period ending December 31, 2025, filed February 24, 2026. Ranked 41 of the 95 Healthcare companies read so far, by the share within reach now.

Organon states over 10,000 employees at December 31, 2025, 1,500 in the United States, 8,900 in commercial, research and development and manufacturing and supply and 1,400 in support functions, so the drug business takes the functional count and the stated support count goes to management of companies (a).

The figures on this page come from the company's own annual report and from BLS staffing patterns for its industries, never from a roster. They are estimates with a stated method. Nothing here says what the company will do: within reach is not a forecast of jobs lost or of savings.

What follows from the reading

Share of working time within reach of AI, on the long-run pace at four in five: 20% now, 36% at the end of 2027, 44% at the end of 2028, 48% at the end of 2030. By the patterns, the work is about 48% desk work, 15% people work and 37% body work. These are the site's industry estimates weighted by the shares below: estimates with a stated method and range, not a forecast of what the company will do. By the same patterns, at the end of 2028 about 53% of the working time stays with people (conversation, in-person and hands-on work), 39% becomes checking a model's work and 5% could be handed over with lighter checks, from the industries' own figures, not the company's roles.

Headcount

10,000 employees as of December 31, 2025 (stated). The filing states approximately 1,500 employees (15%) in the United States including Puerto Rico.

The filing: “As of December 31, 2025, we had over 10,000 employees worldwide with approximately 1,500 (15%) employees in the United States, including Puerto Rico.”

The workforce as industry patterns

What the filing says about the workforce: Approximately 8,900 in commercial, research and development and manufacturing and supply, 1,400 in support functions; about 4,000 in commercialization and 900 in clinical development, safety, medical affairs and registration; 15% in the United States.

Companies read with the same leading pattern

Other companies whose largest staffing pattern is also Pharmaceutical and Medicine Manufacturing, largest first, each read from its own annual report. Within reach now and at the end of 2028, long-run pace, four in five.

• Johnson & Johnson (JNJ, 140,800 employees)19% now, 39% by 2028
• Thermo Fisher Scientific Inc. (TMO, 125,000 employees)20% now, 49% by 2028
• Merck & Co., Inc. (MRK, 75,000 employees)19% now, 41% by 2028
• Pfizer Inc. (PFE, 75,000 employees)19% now, 41% by 2028
• AbbVie Inc. (ABBV, 57,000 employees)19% now, 41% by 2028
• Eli Lilly and Company (LLY, 50,000 employees)19% now, 41% by 2028
• Bristol-Myers Squibb Company (BMY, 32,500 employees)19% now, 41% by 2028
• Amgen Inc. (AMGN, 31,500 employees)19% now, 41% by 2028

What the filing says about AI

13 sentences in the filing name AI. The filing names the evolving AI legislative and regulatory landscape and third-party suppliers' use of AI as risks to privacy, cybersecurity and data accuracy; nothing on its own use in the excerpt.

• “We identified material weaknesses in our internal control over financial reporting, which could impact our ability to report our results of operations and financial condition accurately and in a timely manner. -17- Table of Contents The use of artificial intelligence ("AI") and its legislative and regulatory landscape continues to evolve and makes it difficult to fully understand and assess rel...”
• “If we or our third-party suppliers, logistics providers, and manufacturers do not comply with ethical business practices or with related laws and regulations, including relating to AI use, our reputation, business, financial condition, results of operations or prospects could be harmed.”
• “Our third-party suppliers' use of AI that does not comply with ethical standards, industry recognized AI frameworks or related laws and regulations will expose us to various risks including those relating to privacy, cybersecurity, intellectual property, inaccuracy of data, exposure of our confidential information, producing bias outcomes and overreliance on AI by those third-party suppliers wi...”
• “The use of AI and its legislative and regulatory landscape continues to evolve and makes it difficult to fully understand and assess related risks.”
• “AI-based solutions, including generative AI, are increasingly being used in the pharmaceutical industry, including by us, and we expect to use other systems and tools that incorporate AI-based technologies in the future.”

Its annual reports, year by year

Sentences naming AI in each annual report, counted by one rule, beside the median report in the Index that year. Each count links its filing. Every company, by year and sector

• Fiscal 20210median 0
• Fiscal 20220median 0
• Fiscal 20231median 1
• Fiscal 202410median 4
• Fiscal 202513median 10

Headcount by filing year

As reported in each year's annual report, with the filing. A year marked not read had no figure the reading could take from the report's text.

Limits of this reading

• The functional counts place the support functions apart (rule 6); the commercial, research and manufacturing functions are read together at the drug pattern.

Source: the company's annual report on EDGAR, accession 0001628280-26-011125, the filing. Read by Claude Fable 5.1 under rubric version 1, by the method. A company can write to info@stratussc.com to have its reading checked against its filing.